IXIARO

Phase 3

Valneva SE (VLS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Japanese Encephalitis

View Full Landscape

Drug Information

Target Indication

Japanese Encephalitis

Clinical Trial

NCT01296360

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/31/2009

Ixiaro

Ixiaro is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged two months and older. Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

VLS

Valneva SE

Biotechnology•Europe•NASDAQ

Related Pipeline

Japanese Encephalitis purified inactivated vaccine (IC51)Phase 3

Japanese Encephalitis

VLA1553Phase 3

Chikungunya Virus Infection